Biotech Values

[mouton29]

From an article reporting on Durysta phase 3 trial safety results:

The incidence of both corneal and inflammatory TEAES of interest was higher with the 15-ug dose strength than with the
10-g dose strength of implant. Although most TEAEs showed generally similar incidence rates after the first, second, and third implant administration, corneal TEAs of interest occurred more frequently after repeated treatment. For example, in the 10-and 15-ug bimatoprost implant groups, respectively, corneal endothelial cell loss was reported after the initial administration in 0% (0/197) and 0.5% (1/193) of subjects, after the second administration in 1.6% (3/191) and 3.5% (6/172) of subjects, after the third administration (through the end of the week 52 visit window) in 3.3% (6/183) and 7.0% (11/158) of subjects, and during the 8-month extended follow-up in 5.1% (9/178) and 9.2% (14/152) of subjects who had received 3 administrations.

https://www.aaojournal.org/action/showPdf?pii=S0161-6420%2820%2930555-8